

## PE/Cyanine7 anti-mouse CD45.2 Antibody

<b>Catalog# / Size</b>	109829 / 25 µg 109830 / 100 µg
<b>Clone</b>	104
<b>Regulatory Status</b>	RUO
<b>Other Names</b>	Ly-5.2, LCA
<b>Isotype</b>	Mouse (SJL) IgG2a, κ
<b>Description</b>	CD45.2 is an alloantigen of CD45, expressed by Ly5.2 bearing mouse strains (e.g., A, AKR, BALB/c, CBA/Ca, CBA/J, C3H/He, C57BL, C57BR, C57L, C58, DBA/1, DBA/2, NZB, SWR, 129). CD45, a member of the protein tyrosine phosphatase (PTP) family, is a 180-240 kD glycoprotein expressed on all hematopoietic cells except mature erythrocytes and platelets. There are multiple isoforms in the mouse that play key roles in TCR and BCR signal transduction. These isoforms are very specific to the activation and maturation states of the cell as well as specific cell type. The primary ligands for CD45 are galectin-1, CD2, CD3, CD4, TCR, CD22, and Thy-1.

### Product Details

<b>Verified Reactivity</b>	Mouse
<b>Antibody Type</b>	Monoclonal
<b>Host Species</b>	Mouse
<b>Immunogen</b>	B10.S mouse thymocytes and splenocytes
<b>Formulation</b>	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
<b>Preparation</b>	The antibody was purified by affinity chromatography, and conjugated with PE/Cyanine7 under optimal conditions.
<b>Concentration</b>	0.2 mg/ml
<b>Storage &amp; Handling</b>	The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. <b>Do not freeze.</b>
<b>Application</b>	<a href="#">FC - Quality tested</a>
<b>Recommended Usage</b>	Each lot of this antibody is quality control tested by <a href="#">immunofluorescent staining with flow cytometric analysis</a> . For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 10 <sup>6</sup> cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.
<b>Excitation Laser</b>	Blue Laser (488 nm) Green Laser (532 nm)/Yellow-Green Laser (561 nm)
<b>Application Notes</b>	The 104 antibody does not react with mouse cells expressing the CD45.1 alloantigen. Additional reported applications (for the relevant formats) include: immunoprecipitation <sup>4</sup> , <i>in vivo</i> and <i>in vitro</i> blocking of B cell responses <sup>1,2</sup> , and immunohistochemical staining of acetone-fixed frozen sections <sup>3</sup> .
<b>Additional Product Notes</b>	BioLegend is in the process of converting the name PE/Cy7 to PE/Cyanine7. The dye molecule remains the same, so you should expect the same quality and performance from our PE/Cyanine7 products. Please contact <a href="#">Technical Service</a> if you have any questions.
<b>Application References</b>	<ol style="list-style-type: none"> <li>1. Yakura H, <i>et al.</i> 1983. <i>J. Exp. Med.</i> 157:1077. (Block)</li> <li>2. Yakura H, <i>et al.</i> 1986. <i>J. Immunol.</i> 136:2729. (Block)</li> <li>3. Suzuki K, <i>et al.</i> 2000. <i>Immunity</i> 13:691. (IHC)</li> <li>4. Shen FW, <i>et al.</i> 1986. <i>Immunogenetics</i> 24:146. (IP)</li> <li>5. Baldwin TA and Hogquist KA. 2007. <i>J. Immunol.</i> 179:837.</li> <li>6. Pascal V, <i>et al.</i> 2007. <i>J. Immunol.</i> 179:1751.</li> </ol>
<b>(PubMed link indicates BioLegend citation)</b>	

7. Burman AC, *et al.* 2007. *Blood* 110:1064.
8. Kincaid EZ, *et al.* 2007. *J. Immunol.* 179:3187.
9. Phan TG, *et al.* 2007. *Nature Immunol.* 8:992.
10. Nakano-Yokomizo T, *et al.* 2011. *J. Exp Med.* 208:1661. [PubMed](#)
11. Wen T, *et al.* 2013. *PNAS.* 110:6067. [PubMed](#)
12. Kohlmeier JE, *et al.* 2008. *Immunity.* 29:101. (FC) [PubMed](#)

## Product Citations

1. Gordan S, *et al.* 2020. *Cell Reports.* 29(10):3033-3046.e4. [PubMed](#)
2. Ferrari de Andrade L, *et al.* 2020. *Cancer Immunol Res.* 0.867361111. [PubMed](#)
3. Boyd DF, *et al.* 2020. *Nature.* 587:466. [PubMed](#)
4. Viny AD, *et al.* 2019. *Cell Stem Cell.* 25:682. [PubMed](#)
5. Kurosawa M, *et al.* 2021. *Int J Mol Sci.* 22. [PubMed](#)
6. Koh CH, *et al.* 2020. *Cancer Immunol Res.* 8:698. [PubMed](#)
7. Mylonas K, *et al.* 2015. *Immunobiology.* 220: 924-933. [PubMed](#)
8. Christian LS, *et al.* 2021. *Cell Reports.* 35(6):109118. [PubMed](#)
9. Roeschert I, *et al.* 2021. *Nat Cancer.* 2:312. [PubMed](#)
10. Kumaraswami K, *et al.* 2020. *Int J Mol Sci.* 21:00. [PubMed](#)
11. Gruber T, *et al.* 2020. *JCI Insight.* 5:00. [PubMed](#)
12. Li H, Watowich S 2014. *J Vis Exp.* 85: 51189. [PubMed](#)
13. Schwartz DM *et al.* 2019. *Immunity.* 50(1):106-120 . [PubMed](#)
14. Bangs DJ, *et al.* 2022. *Cell Rep.* 38:110266. [PubMed](#)
15. Kremenovic M, *et al.* 2022. *J Immunother Cancer.* 10. [PubMed](#)
16. Hayatsu N *et al.* 2017. *Immunity.* 47(2):268-283 . [PubMed](#)
17. LaFleur MW, *et al.* 2019. *Nat Immunol.* 20:1335. [PubMed](#)
18. Casali P, *et al.* 2021. *Front Immunol.* 12:761450. [PubMed](#)
19. Blijswijk J, *et al.* 2015. *J Immunol.* 194:307. [PubMed](#)
20. LaMothe RA *et al.* 2018. *Front Immunol.* 0.570138889 . [PubMed](#)
21. Tang Y, *et al.* 2015. *Exp Hematol.* 43: 554-564. [PubMed](#)
22. Kunimoto H, *et al.* 2018. *Cancer Cell.* 33:44. [PubMed](#)
23. Salei N, *et al.* 2020. *J Am Soc Nephrol.* 31:257. [PubMed](#)
24. Ji B, *et al.* 2016. *Cell Death Differ.* 23:759-75. [PubMed](#)
25. Kim P, *et al.* 2015. *J Exp Med.* 212:633. [PubMed](#)
26. Kaplan BLF *et al.* 2018. *Current protocols in toxicology.* 75:11:00 25. [PubMed](#)
27. Sundling C, *et al.* 2021. *Immunity.* 54(5):988-1001.e5. [PubMed](#)
28. Derecka M, *et al.* 2020. *Nat Immunol.* 261:21. [PubMed](#)
29. Progozky F, *et al.* 2021. *Nature.* 599:125. [PubMed](#)
30. Cohen SB *et al.* 2018. *Cell host & microbe.* 24(3):439-446 . [PubMed](#)
31. Malik A *et al.* 2018. *Immunity.* 49(3):515-530 . [PubMed](#)
32. Steinbicker A, *et al.* 2011. *Blood.* 117:4915. [PubMed](#)
33. Moutuou MM, *et al.* 2020. *Methods Mol Biol.* 2111:267. [PubMed](#)
34. Bastow CR, *et al.* 2021. *Proc Natl Acad Sci U S A.* 118. [PubMed](#)
35. Daneshmandi S, *et al.* 2021. *Elife.* 10. [PubMed](#)
36. Beura LK, *et al.* 2018. *Immunity.* 48:327. [PubMed](#)
37. Suan D *et al.* 2017. *Immunity.* 47(6):1142-1153 . [PubMed](#)
38. Tuong ZK, *et al.* 2021. *iScience.* 24:103326. [PubMed](#)
39. Nuro-Gyina PK, *et al.* 2021. *J Immunol.* 207:868. [PubMed](#)
40. Anderson-Baucum E, *et al.* 2021. *Cell Metab.* 33:1883. [PubMed](#)
41. Ulland T, *et al.* 2016. *Nat Commun.* 7:13180. [PubMed](#)
42. Daneshmandi S, *et al.* 2021. *Cell Reports.* 34(10):108831. [PubMed](#)
43. van den Berk P, *et al.* 2020. *Cell Rep.* 33:108533. [PubMed](#)
44. Rodríguez L, *et al.* 2021. *Biomolecules.* 11: . [PubMed](#)
45. Sheng J, *et al.* 2021. *eLife.* 10:00. [PubMed](#)
46. Han P, *et al.* 2020. *Sci Adv.* 6:eaaaz1580. [PubMed](#)
47. Säwen P *et al.* 2018. *eLife.* 7 pii: e41258. [PubMed](#)
48. Luo H, *et al.* 2019. *Cell Rep.* 26:945. [PubMed](#)
49. Zhang B, *et al.* 2021. *Nature.* 599:471. [PubMed](#)
50. Spath S, *et al.* 2022. *iScience.* 25:104998. [PubMed](#)
51. Koronyo Y, *et al.* 2015. *Brain.* 138: 2399-2422. [PubMed](#)
52. Puleston D, *et al.* 2014. *Elife.* 3:3706. [PubMed](#)
53. Muri J, *et al.* 2020. *Cell Reports.* 30(13):4399-4417. [PubMed](#)
54. Yáñez A *et al.* 2017. *Immunity.* 47(5):890-902 . [PubMed](#)
55. Chen S, *et al.* 2018. *Nat Commun.* 9:5298. [PubMed](#)
56. Patterson DG, *et al.* 2021. *J Immunol.* 207:1798. [PubMed](#)
57. Deets KA, *et al.* 2021. *Elife.* 10. [PubMed](#)
58. Sun D, *et al.* 2020. *PLoS Pathog.* 16:e1008361. [PubMed](#)

## RRID

AB\_1186103 (BioLegend Cat. No. 109829)  
 AB\_1186098 (BioLegend Cat. No. 109830)

## Antigen Details

### Structure

Protein tyrosine phosphatase (PTP) family, 180-240 kD

### Distribution

All hematopoietic cells except mature erythrocytes and platelets of the CD45.2 strain of mice

<b>Function</b>	Phosphatase, T and B cell activation
<b>Ligand/Receptor</b>	Galectin-1, CD2, CD3, CD4
<b>Biology Area</b>	Cell Biology, Immunology, Inhibitory Molecules, Innate Immunity, Neuroscience, Neuroscience Cell Markers
<b>Molecular Family</b>	CD Molecules
<b>Antigen References</b>	1. Suzuki K, <i>et al.</i> 2000. <i>Immunity</i> 13:691.
<b>Gene ID</b>	<a href="#">19264</a>


## Related Protocols

[Cell Surface Flow Cytometry Staining Protocol](#)

## Other Formats

Biotin anti-mouse CD45.2, FITC anti-mouse CD45.2, PE anti-mouse CD45.2, Purified anti-mouse CD45.2, APC anti-mouse CD45.2, Alexa Fluor® 488 anti-mouse CD45.2, Alexa Fluor® 647 anti-mouse CD45.2, Pacific Blue™ anti-mouse CD45.2, Alexa Fluor® 700 anti-mouse CD45.2, APC/Cyanine7 anti-mouse CD45.2, PerCP anti-mouse CD45.2, PerCP/Cyanine5.5 anti-mouse CD45.2, PE/Cyanine7 anti-mouse CD45.2, Brilliant Violet 421™ anti-mouse CD45.2, Brilliant Violet 570™ anti-mouse CD45.2, Brilliant Violet 650™ anti-mouse CD45.2, Brilliant Violet 510™ anti-mouse CD45.2, Brilliant Violet 785™ anti-mouse CD45.2, Brilliant Violet 605™ anti-mouse CD45.2, Purified anti-mouse CD45.2 (Maxpar® Ready), PE/Dazzle™ 594 anti-mouse CD45.2, Brilliant Violet 711™ anti-mouse CD45.2, Alexa Fluor® 594 anti-mouse CD45.2, APC/Fire™ 750 anti-mouse CD45.2, TotalSeq™-A0157 anti-mouse CD45.2, TotalSeq™-B0157 anti-mouse CD45.2, TotalSeq™-C0157 anti-mouse CD45.2, Brilliant Violet 750™ anti-mouse CD45.2, Spark Blue™ 550 anti-mouse CD45.2, Spark NIR™ 685 anti-mouse CD45.2

## Product Data



C57BL/6 mouse splenocytes stained with 104 PE/Cyanine7

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

\*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, [www.biolegend.com/ordering#license](http://www.biolegend.com/ordering#license)). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 [www.biolegend.com](http://www.biolegend.com)  
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587